Portal de Periódicos da CAPES

SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIA

2000; Lippincott Williams & Wilkins; Volume: 163; Issue: 1 Linguagem: Inglês

10.1016/s0022-5347(05)67962-1

1527-3792

Claus G. Roehrborn, John D. McConnell, JAIME BONILLA, Sidney Rosenblatt, Perry B. Hudson, GHOLEM H. MALEK, Paul F. Schellhammer, Reginald C. Bruskewitz, Alvin M. Matsumoto, Lloyd H. Harrison, Harold A. Fuselier, Patrick Walsh, Johnny Roy, Gerald L. Andriole, Martin Resnick, Joanne Waldstreicher,

Prostate Cancer Diagnosis and Treatment

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jan 2000SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIA CLAUS G. ROEHRBORN, JOHN McCONNELL, JAIME BONILLA, SIDNEY ROSENBLATT, PERRY B. HUDSON, GHOLEM H. MALEK, PAUL F. SCHELLHAMMER, REGINALD BRUSKEWITZ, ALVIN M. MATSUMOTO, LLOYD H. HARRISON, HAROLD A. FUSELIER, PATRICK WALSH, JOHNNY ROY, GERALD ANDRIOLE, MARTIN RESNICK, JOANNE WALDSTREICHER, and for the PROSCAR§LONG-TERM EFFICACY AND SAFETY STUDY CLAUS G. ROEHRBORNCLAUS G. ROEHRBORN , JOHN McCONNELLJOHN McCONNELL , JAIME BONILLAJAIME BONILLA , SIDNEY ROSENBLATTSIDNEY ROSENBLATT , PERRY B. HUDSONPERRY B. HUDSON , GHOLEM H. MALEKGHOLEM H. MALEK , PAUL F. SCHELLHAMMERPAUL F. SCHELLHAMMER , REGINALD BRUSKEWITZREGINALD BRUSKEWITZ , ALVIN M. MATSUMOTOALVIN M. MATSUMOTO , LLOYD H. HARRISONLLOYD H. HARRISON , HAROLD A. FUSELIERHAROLD A. FUSELIER , PATRICK WALSHPATRICK WALSH , JOHNNY ROYJOHNNY ROY , GERALD ANDRIOLEGERALD ANDRIOLE , MARTIN RESNICKMARTIN RESNICK , JOANNE WALDSTREICHERJOANNE WALDSTREICHER , and for the PROSCAR§LONG-TERM EFFICACY AND SAFETY STUDY View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67962-1AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We analyze patterns of prostate growth in men diagnosed with benign prostatic hyperplasia (BPH) and treated with placebo during 4 years, and determine which baseline parameters were the strongest predictors of growth. Materials and Methods: A total of 3,040 men were enrolled in the 4-year randomized, placebo controlled Proscar Long-Term Efficacy and Safety study. Of these men a subgroup of 10% underwent pelvic magnetic resonance imaging prostate volume measurement at baseline and yearly thereafter. Absolute and percent volume changes during 4 years were calculated in the 164 placebo treated men in the subgroup. The ability of age, baseline prostate volume and prostate specific antigen (PSA) to predict prostate growth in placebo treated patients was assessed by multiple linear regression analyses, receiver operator characteristics curves, and evaluations of growth stratified by tertiles of baseline serum PSA and decades of life. Results: In placebo treated patients a steady increase in mean plus or minus standard deviation prostate volume from year to year was noted (2.5 ± 6.1, 4.9 ± 6.8, 6.4 ± 8.5 and 7.2 ± 8.8 ml. at years 1, 2, 3 and 4, respectively). Mean volume changes at 4 years ranged from −9 to +30 ml. Mean percent change from baseline ranged from 12.5% to 16.6% for men 50 to 59 years old to those 70 to 79 years old. Baseline serum PSA was a strong predictor of growth with 7.4% to 22.0% change at 4 years from the lowest to highest PSA tertiles. Annualized growth rates from baseline were 0.7 ml. per year for PSA 0.2 to 1.3, 2.1 for PSA 1.4 to 3.2 and 3.3 for PSA 3.3 to 9.9 ng./ml. Multiple linear regression analysis showed that serum PSA was a stronger predictor of prostate growth than age or baseline prostate volume. All but 1 man with baseline serum PSA greater than 2.0 ng./ml. had prostate growth during 4 years, and 32.6% of men with serum PSA less than 2.0 exhibited a decrease in volume. Conclusions: Serum PSA is a stronger predictor of growth of the prostate in placebo treated patients than age or baseline prostate volume. Since prostate volume is a risk factor for acute urinary retention and the need for BPH related surgery, the ability of PSA to predict prostate growth may be an important factor when considering individual treatment options for BPH. Such use of PSA represents a shift in paradigm away from focusing solely on symptoms of BPH toward a more comprehensive approach with consideration of predicting and preventing risk factors of BPH related outcomes. References 1 : Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate1990; 17: 241. Google Scholar 2 : The American Urological Association symptom index for benign prostatic hyperplasia. J Urol1992; 148: 1549. Link, Google Scholar 3 : Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores. Urol Clin North Am1995; 22: 299. Google Scholar 4 : Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care1995; 33: AS145. Google Scholar 5 : The 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). : Scientific Communication International Ltd1996. Google Scholar 6 : Prostatism and prostatectomy: the value of urine flow rate measurement in the preoperative assessment for operation. J Urol1977; 117: 70. Link, Google Scholar 7 : Urodynamics in prostatism. I. Prognostic value of uroflowmetry. Scand J Urol Nephrol1988; 22: 109. Google Scholar 8 : Urodynamics in prostatism. IV. Search for prognostic patterns as evaluated by linear discriminant analysis. Scand J Urol Nephrol1988; 114: 84. Google Scholar 9 : Urodynamics in prostatism. II. Prognostic value of pressure-flow study combined with stop-flow test. Scand J Urol Nephrol1988; 114: 72. Google Scholar 10 : Bladder outlet obstruction versus impaired detrusor contractility: the role of uroflow. J Urol1991; 145: 810. Link, Google Scholar 11 : Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol1993; 150: 351. Link, Google Scholar 12 : Benign prostatic hyperplasia: diagnosis and treatment. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services1994. In: No. 8. Google Scholar 13 : The establishment of age specific reference ranges for prostate specific antigen. J Urol1993; 149: 510A. abstract 1188. Google Scholar 14 : Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology1996; 48: 398. Google Scholar 15 : Natural history of prostatism: risk factors for acute urinary retention. J Urol1997; 158: 481. Link, Google Scholar 16 : Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology1999; 53: 473. Google Scholar 17 : Intra- and interobserver variability of MRI prostate volume measurements. Prostate1997; 31: 98. Google Scholar 18 : The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med1998; 338: 557. Google Scholar 19 : Longitudinal measures of prostate volume in a community-based sample: 3.5 year followup in the Olmsted County study of health status and Urinary symptoms among men. J Urol1995; 153: 301A. abstract 291. Google Scholar 20 : Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men?. Urology1995; 45: 64. Google Scholar 21 : Transition zone index (TZI) as a method of assessing benign prostatic hyperplasia: correlation with symptoms, uroflow and detrusor pressure. J Urol1995; 154: 1764. Link, Google Scholar 22 : Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology1995; 46: 631. Google Scholar 23 : Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J1996; 155: 1251. Google Scholar 24 : Effectiveness and safety of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia in the HYCAT study. Urology1996; 47: 159. Google Scholar 25 : Observer variability and reproducibility of transrectal ultrasound in the measurement of prostate volume. Ultrasound Med Biol1995; 21: 1101. Google Scholar 26 : A randomized placebo controlled clinical trial of the safety and efficacy of therapies in men with clinical benign prostatic hyperplasia. N Engl J Med1996; 335: 533. Google Scholar LONG-TERM EFFICACY AND SAFETY STUDYFrom the University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, Department of Veterans Affairs, VA Medical Center, Bay Pines, Florida, Irvine Clinical Research Center, Irvine, California, Jackson Foundation, Madison, Wisconsin, Eastern Virginia Medical School, Norfolk, Virginia, University of Wisconsin, Madison, Wisconsin, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, Wake Forest University School of Medicine, Winston-Salem, North Carolina, Ochsner Clinic, New Orleans, Louisiana, Johns Hopkins Hospital, Baltimore, Maryland, University of Oklahoma, Oklahoma City, Oklahoma, Washington University, St. Louis, Missouri, University Hospital of Cleveland, Cleveland, Ohio and Department of Clinical Research Endocrinology and Metabolism, Merck Research Laboratories, Rahway, New Jersey© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKhera M, Bhattacharya R, Blick G, Kushner H, Nguyen D and Miner M (2011) Changes in Prostate Specific Antigen in Hypogonadal Men After 12 Months of Testosterone Replacement Therapy: Support for the Prostate Saturation TheoryJournal of Urology, VOL. 186, NO. 3, (1005-1011), Online publication date: 1-Sep-2011.Rodriguez E, Skarecky D, Narula N and Ahlering T (2007) Prostate Volume Estimation Using the Ellipsoid Formula Consistently Underestimates Actual Gland SizeJournal of Urology, VOL. 179, NO. 2, (501-503), Online publication date: 1-Feb-2008.Kaplan S (2018) Benign Prostatic HyperplasiaJournal of Urology, VOL. 176, NO. 3, (1061-1063), Online publication date: 1-Sep-2006.Mochtar C, Kiemeney L, van Riemsdijk M, Laguna M, Debruyne F and de la Rosette J (2018) Post-Void Residual Urine Volume is Not a Good Predictor of the Need for Invasive Therapy Among Patients With Benign Prostatic HyperplasiaJournal of Urology, VOL. 175, NO. 1, (213-216), Online publication date: 1-Jan-2006. (2018) RE: THE PROSTATE SPECIFIC ANTIGEN ERA IN THE UNITED STATES IS OVER FOR PROSTATE CANCER: WHAT HAPPENED IN THE LAST 20 YEARS?Journal of Urology, VOL. 174, NO. 3, (1155-1156), Online publication date: 1-Sep-2005.Kaplan S (2018) The Relation of Lower Urinary Tract Symptoms With Life-Style Factors and Objective Measures of Benign Prostatic Enlargement and Obstruction: An Italian SurveyJournal of Urology, VOL. 173, NO. 6, (2058-2058), Online publication date: 1-Jun-2005.CARTER H, LANDIS P, WRIGHT E, PARSONS J and METTER E (2018) CAN A BASELINE PROSTATE SPECIFIC ANTIGEN LEVEL IDENTIFY MEN WHO WILL HAVE LOWER URINARY TRACT SYMPTOMS LATER IN LIFE?Journal of Urology, VOL. 173, NO. 6, (2040-2043), Online publication date: 1-Jun-2005. (2018) RE: THE PROSTATE SPECIFIC ANTIGEN ERA IN THE UNITED STATES IS OVER FOR PROSTATE CANCER: WHAT HAPPENED IN THE LAST 20 YEARS?Journal of Urology, VOL. 173, NO. 6, (2205-2206), Online publication date: 1-Jun-2005.LOEB S, HAN M, ROEHL K, ANTENOR J and CATALONA W (2018) ACCURACY OF PROSTATE WEIGHT ESTIMATION BY DIGITAL RECTAL EXAMINATION VERSUS TRANSRECTAL ULTRASONOGRAPHYJournal of Urology, VOL. 173, NO. 1, (63-65), Online publication date: 1-Jan-2005.STAMEY T, CALDWELL M, McNEAL J, NOLLEY R, HEMENEZ M and DOWNS J (2018) THE PROSTATE SPECIFIC ANTIGEN ERA IN THE UNITED STATES IS OVER FOR PROSTATE CANCER: WHAT HAPPENED IN THE LAST 20 YEARS?Journal of Urology, VOL. 172, NO. 4 Part 1, (1297-1301), Online publication date: 1-Oct-2004. (2018) AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment RecommendationsJournal of Urology, VOL. 170, NO. 2, (530-547), Online publication date: 1-Aug-2003.WRIGHT E, FANG J, METTER E, PARTIN A, LANDIS P, CHAN D and CARTER H (2018) Prostate Specific Antigen Predicts the Long-Term Risk of Prostate Enlargement: Results from the Baltimore Longitudinal Study of AgingJournal of Urology, VOL. 167, NO. 6, (2484-2487), Online publication date: 1-Jun-2002.STAMEY T, JOHNSTONE I, McNEAL J, LU A and YEMOTO C (2018) PREOPERATIVE SERUM PROSTATE SPECIFIC ANTIGEN LEVELS BETWEEN 2 AND 22 NG./ML. CORRELATE POORLY WITH POST-RADICAL PROSTATECTOMY CANCER MORPHOLOGY: PROSTATE SPECIFIC ANTIGEN CURE RATES APPEAR CONSTANT BETWEEN 2 AND 9 NG./ML.Journal of Urology, VOL. 167, NO. 1, (103-111), Online publication date: 1-Jan-2002.STAMEY T, WARRINGTON J, CALDWELL M, CHEN Z, FAN Z, MAHADEVAPPA M, McNEAL J, NOLLEY R and ZHANG Z (2018) MOLECULAR GENETIC PROFILING OF GLEASON GRADE 4/5 PROSTATE CANCERS COMPARED TO BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 166, NO. 6, (2171-2177), Online publication date: 1-Dec-2001.SECH S, MONTOYA J, GIRMAN C, RHODES T and ROEHRBORN C (2018) INTEREXAMINER RELIABILITY OF TRANSRECTAL ULTRASOUND FOR ESTIMATING PROSTATE VOLUMEJournal of Urology, VOL. 166, NO. 1, (125-129), Online publication date: 1-Jul-2001. (2018) EDITORIAL COMMENTJournal of Urology, VOL. 166, NO. 1, (98-98), Online publication date: 1-Jul-2001. (2018) EDITORIAL COMMENTJournal of Urology, VOL. 165, NO. 5, (1525-1525), Online publication date: 1-May-2001. Volume 163Issue 1January 2000Page: 13-20 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordsmagnetic resonance imagingprostatic hyperplasiaprostateprostate-specific antigenMetricsAuthor Information CLAUS G. ROEHRBORN More articles by this author JOHN McCONNELL More articles by this author JAIME BONILLA More articles by this author SIDNEY ROSENBLATT More articles by this author PERRY B. HUDSON More articles by this author GHOLEM H. MALEK More articles by this author PAUL F. SCHELLHAMMER More articles by this author REGINALD BRUSKEWITZ More articles by this author ALVIN M. MATSUMOTO More articles by this author LLOYD H. HARRISON More articles by this author HAROLD A. FUSELIER More articles by this author PATRICK WALSH More articles by this author JOHNNY ROY More articles by this author GERALD ANDRIOLE More articles by this author MARTIN RESNICK More articles by this author JOANNE WALDSTREICHER More articles by this author for the PROSCAR§LONG-TERM EFFICACY AND SAFETY STUDY More articles by this author Expand All Advertisement PDF downloadLoading ...